Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('ecstasy') cytotoxicity

被引:43
作者
Carmo, Helena
Brulport, Marc
Hermes, Matthias
Oesch, Franz
Silva, Renata
Ferreira, Luisa M.
Branco, Paula S.
de Boer, Douwe
Remiao, Fernando
Carvalho, Felix
Schoen, Michael R.
Krebsfaenger, Niels
Doehmer, Johannes
Bastos, Maria de Lourdes
Hengstler, Jan G.
机构
[1] Univ Porto, Fac Pharm, Dept Toxicol, REQUIMTE, P-4050047 Oporto, Portugal
[2] Univ Nova Lisboa, REQUIMTE, CQFB, Chem Dept,Fac Sci & Technol, Monte De Caparica, Portugal
[3] Univ Leipzig, Dept Surg, D-7010 Leipzig, Germany
[4] Univ Leipzig, Ctr Toxicol, D-7010 Leipzig, Germany
[5] Schwarz Biosci GmbH, Dept Pharmacol & Toxicol, Monheim, Germany
[6] GenPharm Tox BioTech AG, D Planegg, Martinsried, Germany
[7] Univ Mainz, Inst Toxicol, D-6500 Mainz, Germany
[8] Univ Hosp Maastricht, Dept Clin Chem, Maastricht, Netherlands
关键词
CYP2D6; ecstasy toxicity; metabolism; polymorphism; 3,4-methylenedioxymethamphetamine;
D O I
10.1097/01.fpc.0000230419.05221.fc
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives Remarkable interindividual differences in 3,4-methylenedioxymethamphetamine ('Ecstasy')-mediated toxicity have been reported in humans. Therefore, we tested whether CYP2D6 or its variant alleles as well as CYP3A4 influence the susceptibility to 3,4-methylenedioxymethamphetamine. Methods 3,4-Methylenedioxymethamphetamine cytotoxicity was determined in V79 cells expressing human wild-type CYP2D6 (CYP2D6*1), the low-activity alleles CYP2D6*2, *9, *10, and *17, as well as human CYP3A4. Metabolites of 3,4-methylenedioxymethamphetamine formed by the different cell lines were quantified by high-performance liquid chromatography/electrochemical detector. Results Toxicity of 3,4-methylenedioxymethamphetamine was clearly increased in cells expressing CYP2D6*1 compared with the parental cells devoid of CYP-dependent enzymatic activity. Toxicity in V79 CYP2D6*1 cells was also higher than in V79 cell lines expressing the low-activity alleles CYP2D6*2, *9, *10, or *17 In contrast to CYP2D6, the CYP3A4 isoenzyme did not enhance 3,4-methylenedioxymethamphetamine toxicity. Formation of the oxidative 3,4-methylenedioxymethamphetamine metabolite N-methyl-alpha-methyldopamine was greatly enhanced in V79 cell line transfected with CYP2D6*1 compared to all other cell lines. The increase in the cytotoxic effects of 3,4-methylenedioxymethamphetamine observed in this cell line was therefore suspected to be a consequence of the production of this metabolite. This was further investigated by testing the cytotoxicity of N-methyl-alpha S-methyldopamine to the control cell line. The results confirmed our hypothesis as the metabolite proved to be more than 100-fold more toxic than the parent compound 3,4-methylenedioxymethamphetamine. Conclusions CYP2D6*1 mediates 3,4-methylenedioxy-methamphetamine toxicity via formation of N-methyl-alpha-methyldopamine. Therefore, it will be important to investigate whether CYP2D6 ultrarapid metabolizers are overrepresented in the cases of 3,4-methylenedioxy-methamphetamine intoxications.
引用
收藏
页码:789 / 799
页数:11
相关论文
共 77 条
[1]   Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs [J].
Bertilsson, L ;
Dahl, ML ;
Dalén, P ;
Al-Shurbaji, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) :111-122
[2]   BIOCHEMICAL AND TOXICOLOGICAL PROPERTIES OF THE OXIDATION-PRODUCTS OF CATECHOLAMINES [J].
BINDOLI, A ;
RIGOBELLO, MP ;
DEEBLE, DJ .
FREE RADICAL BIOLOGY AND MEDICINE, 1992, 13 (04) :391-405
[3]   TOXICITY OF AMINOCHROMES [J].
BINDOLI, A ;
RIGOBELLO, MP ;
GALZIGNA, L .
TOXICOLOGY LETTERS, 1989, 48 (01) :3-20
[4]   Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles [J].
Bogni, A ;
Monshouwer, M ;
Moscone, A ;
Hidestrand, M ;
Ingelman-Sundberg, M ;
Hartung, T ;
Coecke, S .
TOXICOLOGY IN VITRO, 2005, 19 (05) :621-629
[5]   Role of quinones in toxicology [J].
Bolton, JL ;
Trush, MA ;
Penning, TM ;
Dryhurst, G ;
Monks, TJ .
CHEMICAL RESEARCH IN TOXICOLOGY, 2000, 13 (03) :135-160
[6]  
Brauer RB, 1997, TRANSPLANT INT, V10, P229
[7]   Neurotoxicity of ecstasy metabolites in rat cortical neurons, and influence of hyperthermia [J].
Capela, JP ;
Meisel, A ;
Abreu, AR ;
Branco, PS ;
Ferreira, LM ;
Lobo, AM ;
Remiao, F ;
Bastos, ML ;
Carvalho, F .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (01) :53-61
[8]   Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse [J].
Carmo, H ;
Hengstler, JG ;
de Boer, D ;
Ringel, M ;
Carvalho, F ;
Fernandes, E ;
Remiao, F ;
dos Reys, LA ;
Oesch, F ;
Bastos, MD .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (02) :198-205
[9]   Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human [J].
Carmo, H ;
Hengstler, JG ;
de Boer, D ;
Ringel, M ;
Remiao, F ;
Carvalho, F ;
Fernandes, E ;
dos Reys, LA ;
Oesch, F ;
Bastos, MD .
TOXICOLOGY, 2005, 206 (01) :75-89
[10]   Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration [J].
Carmo, H ;
de Boer, D ;
Remiao, F ;
Carvalho, F ;
dos Reys, LA ;
Bastos, MD .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 811 (02) :143-152